S&P 500 may face selling pressure as systematic funds reach full exposure
On Friday, TD Cowen analysts provided a bullish perspective on several stocks within the bioproduction sector, emphasizing the industry’s attractive qualities such as long-term contracts, favorable margins, and growth potential. Despite the mixed sentiment following uneven trends after COVID, the analysts remain optimistic, as reflected in their latest research note titled "MAB Bioproduction: Surveying the Landscape." For investors seeking deeper insights into this sector, InvestingPro offers comprehensive analysis of key players, including detailed financial metrics and expert research reports covering over 1,400 US stocks.
The comprehensive analysis from TD Cowen highlighted four key areas: budget trends, production processes, important themes, and product/vendor positioning. This research supports the firm’s Buy ratings on Danaher Corporation (NYSE:DHR), a prominent player in the Life Sciences Tools & Services industry with a market capitalization of $147.37 billion, Thermo Fisher Scientific Inc. (NYSE:TMO), Avantor, Inc. (NYSE:AVTR), and Repligen Corporation (NASDAQ:RGEN), as noted by analyst Dan Brennan.
The survey conducted for the years 2024-2027 projects monoclonal antibody (mAb) related revenue compound annual growth rates (CAGRs) that align well with TD Cowen’s modeling for DHR and AVTR. Thermo Fisher’s bioproduction business details are not separately disclosed, but the survey’s findings are still seen as positive for the company.
The analysts mentioned that while the market expects a more significant recovery in 2025 after a period of destocking, the survey did not necessarily reflect this sentiment. The survey also revealed that customers prioritize cost-effectiveness and product range when considering changing vendors, suggesting a more competitive pricing environment than previously anticipated.
Thermo Fisher’s market share is expected to decrease according to the survey, yet the company’s actual market share remains significantly higher than what the survey indicates. Feedback on Thermo Fisher’s vertical integration was positive, which could mitigate the impact of the anticipated share loss.
Danaher’s representation in the survey was lower compared to its leading market share, but the survey trends for the company were mostly stable. The macro spending outlook for Danaher was favorable, although the vendor-specific perspective was neutral. According to InvestingPro data, Danaher maintains strong financials with $23.88 billion in revenue and a GOOD overall financial health score. The company has maintained dividend payments for 33 consecutive years, with a recent dividend growth of 33.33%. Currently trading near its 52-week low, Danaher’s stock appears to be fairly valued based on InvestingPro’s Fair Value analysis.
Avantor’s share in excipients also appeared underrepresented in the survey. However, similar to Danaher, the overall spending outlook was positive, with a neutral view on the company’s specific market share, which also remained stable.
Repligen was expected to lose a modest market share, yet the survey was biased towards a greater upstream intensification, which would benefit the company. Additionally, there was a positive bias towards process development spending, which precedes commercial expenditure.
The survey identified Sartorius Stedim (EPA:STDM) Biotech (not covered by TD Cowen) and Merck (NSE:PROR) KGaA (ETR:MRK DE) as the most significant share gainers in the market. Despite these shifts, the overall sentiment from TD Cowen remains positive for the bioproduction market and the companies they cover. For investors interested in deeper analysis of these market dynamics, InvestingPro offers extensive financial metrics, including 15+ additional ProTips and comprehensive valuation tools to help make informed investment decisions.
In other recent news, Danaher Corporation reported its fourth-quarter 2024 earnings, revealing a slight miss in earnings per share (EPS) compared to forecasts but surpassing revenue expectations. The company posted an EPS of $2.14, just below the anticipated $2.15, while revenue reached $6.54 billion, exceeding the forecast of $6.39 billion. Additionally, Danaher announced an 18.5% increase in its regular quarterly cash dividend, raising it from $0.27 to $0.32 per share. This move reflects the company’s confidence in its financial strength and commitment to shareholder value.
Furthermore, Danaher appointed Charles W. Lamanna to its Board of Directors and amended its 2007 Omnibus Incentive Plan to provide clarity and security for participants’ beneficiaries. The company’s strategic focus on diagnostics and life sciences segments has shown resilience amid market variability. Analysts from firms like TD Cowen and Bank of America have noted Danaher’s strong order growth in its bioprocessing business, indicating potential for sustained revenue growth. These developments highlight Danaher’s ongoing efforts to enhance its market position and financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.